Charles A. Reinhart III is CFO at Pacira Pharmaceuticals, Inc. (PCRX). They have made 6 open-market trades across 1 company since 2018, most recently 2024-06-12.
CIK 0001470871
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 6 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| PCRX | 51,867 | $1.9M |
Shares reported on the most recent Form 4, priced at the 2024-06-13 close.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| PCRX | SELL | 2023-06-06 | 2023-06-07 | $38.22 | $152K | +9.4% | +1.4% | -7.0% |
| PCRX | SELL | 2022-06-06 | 2022-06-08 | $61.37 | $309K | -9.5% | -2.7% | -12.5% |
| PCRX | SELL | 2021-06-04 | 2021-06-08 | $61.04 | $323K | -1.9% | -7.4% | -7.2% |
| PCRX | SELL | 2020-06-04 | 2020-06-08 | $46.33 | $138K | -6.4% | +18.8% | +26.3% |
| PCRX | SELL | 2019-06-04 | 2019-06-06 | $42.91 | $47K | +3.1% | +1.9% | -13.9% |
| PCRX | SELL | 2018-06-04 | 2018-06-06 | $33.02 | $23K | -1.3% | -9.8% | +23.9% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.